Form 4: Relay Therapeutics Officer Acquires Shares Through Employee Stock Purchase Plan

Relay Therapeutics, Inc. Chief Corporate Development Officer Peter Rahmer acquired 5,000 shares of common stock at $2.94 per share through the company's Employee Stock Purchase Plan.

Summary

• Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, Inc. (RLAY), acquired 5,000 shares of common stock.
• The transaction occurred on June 30, 2025, at a price of $2.94 per share.
• The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan (ESPP).
• The purchase price of $2.94 per share represents 85% of the closing price of the Issuer's common stock on June 30, 2025.
• Following this transaction, Peter Rahmer beneficially owns a total of 395,081 shares, which includes 204,715 shares underlying Restricted Stock Units (RSUs).
• This transaction is exempt under SEC Rules 16b-3(d) and 16b-3(c) and is being voluntarily reported.

Sentiment

Score: 6

Explanation: The acquisition of shares by an officer, even through an ESPP, can be viewed as a positive signal of confidence in the company's future. While an ESPP purchase is a routine event, it still represents an insider increasing their stake, which is generally seen favorably.

Positives

• An officer acquiring shares, even through an ESPP, can signal confidence in the company's future prospects.
• The acquisition was made at a discounted price of $2.94 per share, representing 85% of the closing price, which is a benefit of the ESPP.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details a routine insider transaction under an Employee Stock Purchase Plan. Such plans are common across various industries, including biotechnology, as a means to encourage employee ownership and align interests with shareholders. This specific transaction does not provide broader industry insights or competitive context.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a standard component of compensation packages in many publicly traded companies, including those in the biotechnology sector.
• The discount offered (15% in this case, as the purchase was at 85% of the closing price) is typical for such plans, often ranging from 5% to 15%.
• This transaction aligns with common industry practices for employee equity participation.

Related Party Transactions

• The acquisition of shares through the Employee Stock Purchase Plan (ESPP) is a standard employee benefit program and is not typically categorized as a "related party transaction" in the context of unusual or non-arm's length dealings.

Stakeholder Impact

• Shareholders: The acquisition by an officer may be viewed positively as it aligns management's interests with shareholders.
• Employees: The transaction highlights the existence and utilization of the company's Employee Stock Purchase Plan, which is a benefit for participating employees.

Key Dates

Keywords

Relay Therapeutics, RLAY, Peter Rahmer, SEC Form 4, Insider Trading, Stock Purchase, Employee Stock Purchase Plan, ESPP, Common Stock, Officer Transaction, Corporate Development Officer